Measurements of charged current lepton universality and |Vus| using tau lepton decays to e- (e) ( ), - ( ) ( ), - ( ), and K- ( ).

9 pages, 12 encapsulated postscript figures, submitted to Physical Review LettersInternational audienceUsing 467 $fb^{-1}$ of $e^+e^-$ annihilation data collected with the BaBar detector, we measure $\frac{{\cal{B}}(\tau^- \to \mu^- \bar{\nu}_\mu \nu_\tau)}{{\cal{B}}(\tau^- \to e^- \bar{\nu}_e \nu_\tau)} = (0.9796 \pm 0.0016 \pm 0.0036)$, $\frac{{\cal{B}}(\tau^- \to \pi^- \nu_\tau)}{{\cal{B}}(\tau^- \to e^- \bar{\nu}_e \nu_\tau)} = (0.5945 \pm 0.0014 \pm 0.0061)$, and \frac{{\cal{B}}(\tau^- \to \K^- \nu_\tau)}{{\cal{B}}(\tau^- \to e^- \bar{\nu}_e \nu_\tau)} = (0.03882 \pm 0.00032 \pm 0.00057), where the uncertainties are statistical and systematic, respectively. From these precision measurements we test the Standard Model assumption of $\mu$-$e$ and $\tau$-$\mu$ charged current lepton universality and also obtain a value for $|V_{us}| = 0.2255 \pm 0.0024$, which is consistent with the prediction from the unitarity of the Cabibbo-Kobayashi-Maskawa matrix

Stable luminescent iridium(III) complexes with bis(N-heterocyclic carbene) ligands : photo-stability, excited state properties, visible-light-driven radical cyclization and CO2 reduction, and cellular imaging

2015-2016 > Academic research: refereed > Publication in refereed journalVersion of RecordPublishe

Computed tomographic biomarkers in idiopathic pulmonary fibrosis: the future of quantitative analysis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with great variability in disease severity and rate of progression. The need for a reliable, sensitive, and objective biomarker to track disease progression and response to therapy remains a great challenge in IPF clinical trials. Over the past decade, quantitative computed tomography (QCT) has emerged as an area of intensive research to address this need. We have gathered a group of pulmonologists, radiologists and scientists with expertise in this area to define the current status and future promise of this imaging technique in the evaluation and management of IPF. In this Pulmonary Perspective, we review the development and validation of six computer-based QCT methods and offer insight into the optimal use of an imaging-based biomarker as a tool for prognostication, prediction of response to therapy, and potential surrogate endpoint in future therapeutic trials

Computed tomographic biomarkers in idiopathic pulmonary fibrosis: the future of quantitative analysis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with great variability in disease severity and rate of progression. The need for a reliable, sensitive, and objective biomarker to track disease progression and response to therapy remains a great challenge in IPF clinical trials. Over the past decade, quantitative computed tomography (QCT) has emerged as an area of intensive research to address this need. We have gathered a group of pulmonologists, radiologists and scientists with expertise in this area to define the current status and future promise of this imaging technique in the evaluation and management of IPF. In this Pulmonary Perspective, we review the development and validation of six computer-based QCT methods and offer insight into the optimal use of an imaging-based biomarker as a tool for prognostication, prediction of response to therapy, and potential surrogate endpoint in future therapeutic trials